It showed that patients with HER2 negative breast cancer with residual disease after NACT who received adjuvant capecitabine had higher rates of five-year disease-free survival (DFS) and overall survival (OS) when compared to those who received no further treatment. This evidence concerns the gene ERBB2 and breast carcinoma.